← back to search

Daniel Heudobler

University Hospital Regensburg · DE
🔎 Find collaborators in Oncology · Surgery →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Oncology · Surgery
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Cholangiocarcinoma and Gallbladder Cancer Studies, and Acute Myeloid Leukemia Research.
h-index
17
citations
1,603
works
134
NIH funding
primary concept
Medicine
email

Recent publications

Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
BMC Medicine 2026cited by 1position: middledoi
Additional file 1 of Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
Open MIND 2026cited by 0position: middledoi
Additional file 1 of Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
Figshare 2026cited by 0position: middledoi
Primary and secondary metastatic dissemination: multiple routes to cancer-related death
Molecular Cancer 2025cited by 6position: middledoi
MetInfilt: A prospective trial highlighting the importance of the histological growth pattern in brain metastases
Translational Oncology 2025cited by 5position: middledoi
Preliminary effectiveness of social prescription and virtual patient information in increasing tertiary prevention among cancer patients (ESPRIT): protocol for a single-centre, randomised controlled pilot trial
BMJ Open 2025cited by 0position: middledoi
NSCLC mit synchroner Oligometastasierung zum Zeitpunkt Erstdiagnose. Einfluss unterschiedlicher Systemtherapien auf die Prognose. Eine BZKF-Analyse.
Pneumologie 2025cited by 0position: lastdoi
NSCLC mit synchroner Oligometastasierung zum Zeitpunkt Erstdiagnose. Einfluss von System- und Lokaltherapie auf die Prognose. Eine BZKF-Analyse
Pneumologie 2025cited by 0position: lastdoi
Overcoming challenges in obtaining informed consent in cancer clinical trials
Patient Education and Counseling 2025cited by 0position: middledoi
OGCT-04 PROSPECTIVE IMAGING-GUIDED BIOPSY TRIAL OF THE MACRO METASTASIS-BRAIN PARENCHYMA INTERFACE (METINFILT STUDY)
Neuro-Oncology Advances 2025cited by 0position: middledoi
P11.39.B IMPORTANCE OF THE HISTOLOGICAL GROWTH PATTERN IN BRAIN METASTASES. A PROSPECTIVE IMAGING-GUIDED BIOPSY TRIAL
Neuro-Oncology 2025cited by 0position: middledoi
Imaging–guided prospective biopsy trial of the macro metastasis–brain parenchyma interface highlighting the importance of the histological growth pattern in brain metastases
Brain and Spine 2025cited by 0position: middledoi
How to improve informed consent processes in clinical trials with cancer patients: a qualitative analysis of multidisciplinary experts’ perspectives
BMC Medical Ethics 2025cited by 0position: middledoi
611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors
Annals of Oncology 2024cited by 12position: middledoi
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany
European Journal of Cancer 2024cited by 3position: middledoi
Cellular liquid biopsy provides unique chances for disease monitoring, preclinical model generation and therapy adjustment in rare salivary gland cancer patients
Molecular Oncology 2024cited by 1position: middledoi
A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of Cln-049 for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease
Blood 2024cited by 1position: middledoi
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Nature Medicine 2023cited by 247position: middledoi
Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥ 60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase
Haematologica 2023cited by 12position: firstdoi
CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.
Journal of Clinical Oncology 2023cited by 8position: middledoi
Critical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre
British Journal of Cancer 2022cited by 29position: middledoi
Identification of Disparities in Personalized Cancer Care—A Joint Approach of the German WERA Consortium
Cancers 2022cited by 25position: middledoi
Abstract CT002: BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors
Cancer Research 2022cited by 17position: middledoi
Case Report: Extramedullary Acute Promyelocytic Leukemia: An Unusual Case and Mini-Review of the Literature
Frontiers in Oncology 2022cited by 10position: lastdoi
Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis
Leukemia & lymphoma/Leukemia and lymphoma 2022cited by 8position: lastdoi
All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma
Frontiers in Oncology 2022cited by 5position: lastdoi
Association of epidemiological and clinical features with PCR cycle threshold values of SARS-CoV-2 infection: a cross-sectional study
Pathogens and Global Health 2022cited by 3position: middledoi
Thorakale Onkologie – metastasierte Stadien
Der Onkologe 2022cited by 0position: middledoi
Mapping the Regional Distribution of Molecular Tumor Board Patients and Identifying White Spots in our Catchment Area – a Joint Approach of the CCC WERA Alliance
medRxiv 2022cited by 0position: middledoi
Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson’s disease: Balancing immunosuppression
International Journal of Infectious Diseases 2021cited by 19position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Florian Lüke · Hershey (United States)13 papers (2018–2025)Tobias Pukrop · University of Regensburg12 papers (2017–2025)Wolfgang Herr · Johannes Gutenberg University Mainz12 papers (2017–2025)Albrecht Reichle · University Hospital Regensburg7 papers (2017–2023)Raquel Blazquez · University of Regensburg6 papers (2018–2025)Daniel Wolff · Polyclinic Medical Center6 papers (2019–2025)Daniela Sparrer · University of Regensburg5 papers (2025–2025)Markus J. Riemenschneider · University Hospital Regensburg5 papers (2018–2025)Katja Evert · University of Regensburg5 papers (2025–2025)Karl-Michael Schebesch · Paracelsus Medizinische Privatuniversität4 papers (2025–2025)Ernst Holler · Polyclinic Medical Center4 papers (2013–2020)Daniela Hirsch · University of Regensburg4 papers (2025–2025)Anne Herrmann · University of Lausanne4 papers (2021–2025)Winfried Alsdorf · Universität Hamburg4 papers (2021–2024)Martin Vogelhuber · University Hospital Regensburg4 papers (2017–2022)Nils Ole Schmidt · University Hospital Regensburg4 papers (2025–2025)Christian Doenitz · University of Regensburg4 papers (2025–2025)Andréas Mackensen · Friedrich-Alexander-Universität Erlangen-Nürnberg4 papers (2021–2024)Tommaso Araceli · University of Regensburg4 papers (2025–2025)Christina Wendl · Technical University of Munich4 papers (2025–2025)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Oncology · Surgery →